<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516577</url>
  </required_header>
  <id_info>
    <org_study_id>2020073195</org_study_id>
    <nct_id>NCT04516577</nct_id>
  </id_info>
  <brief_title>To Assess the Severity of Pulmonary Alveolar Proteinosis Through Different Methods （DSS, SPSP and SPSP II）</brief_title>
  <official_title>Shanghai Pulmonary Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      By updating the chest HRCT scoring criteria of patients with pulmonary alveolar proteinosis,&#xD;
      a new and more perfect system for evaluating the severity of alveolar proteinosis will be&#xD;
      established.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In past, investigators summarized a method that was the severity and prognosis of pulmonary&#xD;
      alveolar proteinosis (SPSP) to assess the severity and prognosis of patients. The SPSP&#xD;
      included five aspectes: smoking, symptom, PaO2, chest CT score and DLCO %predicetd. But the&#xD;
      chest CT score only foucused on range of lesions, and inaccurate. So, investigators plan to&#xD;
      adopt new score which involves the assessing to range and density.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The severity and prognosis of pulmonary alveolar proteinosis</measure>
    <time_frame>From July 2020 to Decomber 2020</time_frame>
    <description>The second severity and prognosis score of PAP (SPSP II) involves the range and density of lesion in chest CT of patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pulmonary Alveolar Proteinosis</condition>
  <arm_group>
    <arm_group_label>Shanghai Pulmonary Hospital</arm_group_label>
    <description>Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peking Union Medical College Hospital</arm_group_label>
    <description>Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assesssing the severity of pulmonary alveolar proteinosis</intervention_name>
    <description>Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.</description>
    <arm_group_label>Peking Union Medical College Hospital</arm_group_label>
    <arm_group_label>Shanghai Pulmonary Hospital</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients had be diagnosed with autoimmune pulmonary alveolar proteinosis. Every patient&#xD;
        had a complete medical history, chest HRCT, pulmonary function and arterial blood gas&#xD;
        analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patients had be diagnosed with autoimmune pulmonary alveolar proteinosis through&#xD;
             pathology or bronchial alveolar lavage fluid (BALF).&#xD;
&#xD;
          -  The patients are old than 18 year.&#xD;
&#xD;
          -  .Every patient had a complete medical history, chest HRCT, pulmonary function and&#xD;
             arterial blood gas analysis.&#xD;
&#xD;
          -  The patients have high level antibody of GM-CSF in serum or BALF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patients had a congenital or secondary pulmonary alveolar proteinosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jiuwu Bai</last_name>
    <phone>862165115006</phone>
    <email>yv59@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiuwu Bai, Dr</last_name>
    <phone>86013651602925</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai pulmonary hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-fu Xu, MD</last_name>
      <phone>+8613321922898</phone>
      <email>jfxucn@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 30, 2020</last_update_submitted>
  <last_update_submitted_qc>August 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Chief of Respiratory and Critical Care Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

